US Edition
Caris Life Sciences Files Registration Statement for Proposed Initial Public Offering
- On May 23, 2025, Caris Life Sciences submitted a Form S-1 registration statement in Irving, Texas, to the SEC for a planned stock market debut involving its Class A shares.
- The filing follows Caris’s growth as a patient-centric, AI-driven precision medicine company headquartered in Irving with multiple global offices.
- Caris uses advanced molecular profiling, AI, machine learning, and a large clinico-genomic database to develop diagnostics for early detection and therapy selection.
- The number of shares and price range remain undetermined, with Nasdaq Global Select Market listing planned under the ticker symbol 'CAI'.
- The registration is pending SEC effectiveness, and no securities may be sold beforehand, signaling Caris’s intent to expand via public investment amid evolving market conditions.
25 Articles
25 Articles
Denton Record-Chronicle
Caris Life Sciences Files Registration Statement for Proposed Initial Public Offering
IRVING, Texas, May 23, 2025 /PRNewswire/ -- Caris Life Sciences® ("Caris"), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange…
Caris Life Sciences discloses rise in revenue in US IPO filing - Regional Media News
(Reuters) -Biotech company Caris Life Sciences filed its paperwork to go public in the U.S. on Friday as the stock market shows signs of recovery after tariff shocks. Irving, Texas-based firm reported a revenue rise to $412.3 million in 2024 compared with $306.1 million in 2023, according to the regulatory filing. Activity in the U.S. IPO market had declined after a strong start in 2025 due to an ever-evolving tariff environment, geopolitical un…
Coverage Details
Bias Distribution
- 71% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
